Kelun-Biotech Presents Pivotal Phase II Data For Lunbotinib Fumarate (A400/EP0031) In RET Fusion-Positive NSCLC At 2026 ASCO

(MENAFN - PR Newswire) CHENGDU, China, May 29, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990) announced that at the 2026 American Society of Clinical ...